Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/17/2017 05/18/2017 05/19/2017 05/22/2017 05/23/2017 Date
16.875(c) 16.75(c) 17.625(c) 18(c) 17.875(c) Last
462 159 622 615 315 018 382 186 68 783 Volume
-3.57% -0.74% +5.22% +2.13% -0.69% Change
More quotes
Financials ( GBP)
Sales 2017 16,0 M
EBIT 2017 -33,0 M
Net income 2017 -24,2 M
Finance 2017 15,5 M
Yield 2017 -
Sales 2018 27,8 M
EBIT 2018 -29,8 M
Net income 2018 -33,3 M
Finance 2018 6,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 4,95x
EV / Sales2018 3,19x
Capitalization 94,7 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
04/26 VERNALIS : Gets EUR2 Million Milestone Payments From Servier Partnership
04/24 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
04/21 VERNALIS : Cough Cold Treatment Drug Application Suffers Setback
04/21 VERNALIS : *panmure cuts vernalis plc to 'hold' ('buy') - target 65 pence
04/21 VERNALIS : receives a $2 million milestone payment from one of its drug discover..
04/21 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
04/21 VERNALIS PLC : FDA Issues a Complete Response Letter on CCP-07 NDA
03/29 VERNALIS : Block listing Interim Review
03/06 VERNALIS : Partners With Servier On Oncology Drug-Discovery
03/06 VERNALIS : and Servier enter into a new drug discovery collaboration strengtheni..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/28EuroBiotech Report: AstraZeneca HQ, Barcelona’s EMA bid, argenx IPO, Circassi..
1
04/27Vernalis plc $VNLPY Upgraded by Zacks Investment Research to Hold  
04/26Vernalis plc upgraded by Zacks Investment Research to hold.  
04/21FDA rejects Vernalis' marketing application cough/cold med CCP-07  
04/21FDA rejects Vernalis’ cough cold treatment
1
More tweets
Qtime:5
News from SeekingAlpha
04/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017
04/21 FDA rejects Vernalis' marketing application cough/cold med CCP-07
02/21 Vernalis reports 1H results
2016 Vernalis reports FY16 results
2016 Vernalis ADR reports 6M'15 results
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,58  GBP
Spread / Average Target 225%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-47.06%123
INCYTE CORPORATION34.07%27 528
QUINTILES IMS HOLDINGS..9.20%18 382
LONZA GROUP AG18.67%15 234
CELLTRION, INC.--.--%10 254
SEATTLE GENETICS, INC.26.21%9 492
More Results